New guideline inclusion for Cerebrolysin^® in stroke

On June 14, 2024, it has been announced that the Ministry of Health of the Republic of Azerbaijan included Cerebrolysin^® into the “Clinical Guideline for Medical Rehabilitation of Ischemic Stroke”. In recent years local neurorehabilitation- or stroke societies in various countries worldwide have enlarged their scope of recommendations from evaluating the available evidence in neurorehabilitation.

While some years ago only technology-focused therapies like robotics or physical medicine related to physiotherapy or occupational therapy have been evaluated nowadays also pharmacological agents are increasingly in the contextual focus of neurororehabilitation medicine.

Naturally, when state-of-the-art search strategies are applied by national- or international guideline committees they do not only come across strong clinical evidence of Cerebrolysin^® in connection with motor recovery, they also find an increasing number of guideline recommendations from other countries.

In this respect the recommendation from Azerbaijan represents another milestone for the international acknowledgement of Cerebrolysin^® while on the other hand it is increasingly the norm, demonstrating that the agent is an essential part of standard therapy after post-stroke complications, particularly for patients suffering from motor impairment.

Main message of the Cerebrolysin^® inclusion
The use of Cerebrolysin^® is recommended to improve the functional results of the disease within 3 months in patients of different age groups, regardless of the location of the vascular lesion of the brain. The drug should be administered within the first 12 hours after ischemic stroke: 30 ml once a day for 10 days (intravenous drip).